 |
|
Immune molecule that plays a powerful role in avoiding organ rejection identified
June 17, 2008When a mouse's immune system is deciding whether to reject a skin graft, one powerful member of a molecular family designed to provoke such a response can effectively reduce the visibility of the mouse's own cells and help the graft survive, researchers say.
"This is a molecule with huge potential to regulate immune response," Dr. Anatolij Horuzsko, reproductive immunologist at the Medical College of Georgia Center for Molecular Chaperone/Radiobiology and Cancer Virology, says of HLA-G dimer.
Dimer appears to be the most powerful among several known forms of HLA-G at inhibiting the immune response, researchers have found. Fetuses use this natural mechanism to hide from the mother's immune system and it's at work in some transplant patients as well.
Now that the scientists know which HLA-G is best at down-regulating the immune response and how it works, they believe the molecule's action can be augmented in people with organ transplants and autoimmune disease and turned down to help fight a tumor. Measuring endogenous levels of HLA-G dimer may also help physicians identify which transplant patients require little, if any, immune suppression.
Research published online in Proceedings of the National Academy of Sciences details that when HLA-G dimer binds with its inhibitory receptor, ILT4, it triggers a signaling pathway in which immune molecules IL-6 and STAT3 play a major role. "Biologically this is an interaction that requires several important suppressive molecules," says Dr. Horuzsko, the study's corresponding author and a faculty member in the MCG Schools of Medicine and Graduate Studies.
They looked at the resulting strong signaling in culture, then measured its impact on skin graft survival in mice and found it prolonged survival. Now Dr. Horuzsko is working with Dr. Laura Mulloy, chief of the Section of Nephrology, Hypertension and Transplantation Medicine in the MCG School of Medicine, to see if this dimer form is at work in kidney transplant patients who avoid rejection.
HLA-G dimer's target is another MHC molecule, which is essentially an individual's unique tissue signature; HLA-G itself is a type of MHC. In fact, HLA - human leukocyte antigen - matching is done for organ and bone marrow transplants to try minimize the recipient's reaction to the new organ. Transplant patients also take drugs that broadly dampen the immune response but can leave them more vulnerable to infections and disease.
Dr. Horuzsko notes that HLA-G can work through other cells, not just MHC molecules, and that not every HLA-G form is good at down-regulating MHC.
He plans to look at HLA-G dimer levels in tumor patients as well. "Tumors already down- regulate MHC molecules," he says, referencing how tumors turn down their tissue expression so they can fly below the radar of the immune system. "We need to see what form of HLA-G cancers - including leukemia, lymphoma, melanoma and breast cancer - use and see their level of expression." He notes that HLA-G isn't the only mechanism cancers use to escape the immune response but that being able to control a tumor's use of this molecule could offer a new way to target tumors for natural destruction.
A recent grant from the National Multiple Sclerosis Society is enabling studies of whether down-regulating MHC expression in multiple sclerosis patients can slow or arrest the immune system's attack of the nerve's protective covering. "The expression of the MHC molecule for some reason goes up - an infection might trigger the recognition of your own tissue - and the immune system attacks," says Dr. Horuzsko. "We can generate a mouse with MS-like disease and target the HLA-G inhibitory receptor to see if it effectively down-regulates the disease." He'll look to see which, if any, of the HLA-G forms are most powerful in this autoimmune scenario.
Medical College of Georgia
Now that the scientists know which HLA-G is best at down-regulating the immune response and how it works, they believe the molecule's action can be augmented in people with organ transplants and autoimmune disease and turned down to help fight a tumor. Measuring endogenous levels of HLA-G dimer may also help physicians identify which transplant patients require little, if any, immune suppression.
Research published online in Proceedings of the National Academy of Sciences details that when HLA-G dimer binds with its inhibitory receptor, ILT4, it triggers a signaling pathway in which immune molecules IL-6 and STAT3 play a major role. "Biologically this is an interaction that requires several important suppressive molecules," says Dr. Horuzsko, the study's corresponding author and a faculty member in the MCG Schools of Medicine and Graduate Studies.
They looked at the resulting strong signaling in culture, then measured its impact on skin graft survival in mice and found it prolonged survival. Now Dr. Horuzsko is working with Dr. Laura Mulloy, chief of the Section of Nephrology, Hypertension and Transplantation Medicine in the MCG School of Medicine, to see if this dimer form is at work in kidney transplant patients who avoid rejection.
HLA-G dimer's target is another MHC molecule, which is essentially an individual's unique tissue signature; HLA-G itself is a type of MHC. In fact, HLA - human leukocyte antigen - matching is done for organ and bone marrow transplants to try minimize the recipient's reaction to the new organ. Transplant patients also take drugs that broadly dampen the immune response but can leave them more vulnerable to infections and disease.
Dr. Horuzsko notes that HLA-G can work through other cells, not just MHC molecules, and that not every HLA-G form is good at down-regulating MHC.
He plans to look at HLA-G dimer levels in tumor patients as well. "Tumors already down- regulate MHC molecules," he says, referencing how tumors turn down their tissue expression so they can fly below the radar of the immune system. "We need to see what form of HLA-G cancers - including leukemia, lymphoma, melanoma and breast cancer - use and see their level of expression." He notes that HLA-G isn't the only mechanism cancers use to escape the immune response but that being able to control a tumor's use of this molecule could offer a new way to target tumors for natural destruction.
A recent grant from the National Multiple Sclerosis Society is enabling studies of whether down-regulating MHC expression in multiple sclerosis patients can slow or arrest the immune system's attack of the nerve's protective covering. "The expression of the MHC molecule for some reason goes up - an infection might trigger the recognition of your own tissue - and the immune system attacks," says Dr. Horuzsko. "We can generate a mouse with MS-like disease and target the HLA-G inhibitory receptor to see if it effectively down-regulates the disease." He'll look to see which, if any, of the HLA-G forms are most powerful in this autoimmune scenario.
Medical College of Georgia
Immune Response Current Events and Immune Response News RSSDNA of good bacteria drives intestinal response to infection
A new study shows that the DNA of so-called "good bacteria" that normally live in the intestines may help defend the body against infection.
Scientists unmask key HIV protein, open door for more powerful AIDS drugs
University of Michigan scientists have provided the most detailed picture yet of a key HIV accessory protein that foils the body's normal immune response.
OHSU Cancer Institute researcher: radiation, immunotherapy gives greater effectiveness
Oregon Health & Science University Cancer Institute researchers have found the right formula of radiation and immunotherapy for fighting lung cancer tumors in mice, which they hope will translate to better treatment in human lung cancers.
ESF study helps stop drugs slipping through safety net
Recent advances in genetic screening will lead to safer pharmaceutical drugs, with reduced adverse side effects, if the methods are incorporated in clinical development.
Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS
Key differences in immune system signaling and the production of specific immune regulatory molecules may explain why some primates are able to live with an immunodeficiency virus infection without progressing to AIDS-like illness, unlike other primate species, including rhesus macaques and humans, that succumb to disease.
Colorful spy tactics track live cells supporting cancerous tumors
A new advance in cellular imaging is allowing scientists to better understand the movement of cells in the area around tumors, also known as the tumor microenvironment.
Wistar researchers invigorate 'exhausted' immune cells
In battles against chronic infections, the body's key immune cells often become exhausted and ineffective. Researchers at The Wistar Institute have found a way to restore vigor to these killer T cells by blocking a key receptor on their surface, findings that may advance the development of new therapies for diseases such as HIV, hepatitis B and C, and cancer.
Vaccine against HER2-positive breast cancer offers complete protection in lab
Researchers at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 therapy - without any toxicity.
New tool to speed cancer therapy approval available
Although cancer remains a leading cause of death in America, it can take up to 12 years to bring a new anti-cancer agent before the FDA and the success rate for approval is only five to 10 percent. That means many research hours and dollars are wasted chasing avenues that will not bring fruit.
Mate selection more biologically determined in some human populations
Some human populations may rely on biological factors in addition to social factors when selecting a mate. In a recent study, published September 12 in the open-access journal PLoS Genetics, scientists in China, France, and the United Kingdom report genomic data showing that immunity traits may be involved in mate choice in some human populations.
More Immune Response Current Events and Immune Response News Articles
 | Immunity: The Immune Response to Infectious and Inflammatory Disease (Primers in Biology) by Anthony DeFranco, Richard Locksley, Miranda Robertson An understanding of the immune system is central to the understanding of how the body interacts with its surroundings, and how it both protects itself and responds to infectious disease. But what processes underpin the body's response to infection? How does our immune system remember its previous encounters? And what happens when the tight regulation of the immune system fails? Immunity:... |
 | Primer to The Immune Response by Tak W. Mak, Mary Saunders Primer to The Immune Response is an invaluable resource for college students, university undergraduates and students in medicine and other health professions who need a concise but complete and understandable introduction to immunology.This book is written in the same engaging conversational style as the published reference book The Immune Response: Basic and Clinical Principles and conveys the... |
 | The Immune Response: Basic and Clinical Principles by Tak W. Mak, Mary Saunders The Immune Response is a unique reference work covering the basic and clinical principles of immunology in a modern and comprehensive fashion. Written in an engaging conversational style, the book conveys the broad scope and fascinating appeal of immunology. The book is beautifully illustrated with superb figures as well as many full color plates. This extraordinary work will be an invaluable... |
 | The Innate Immune Response to Infection |
 | Handbook of Immune Response Genes by Tak W. Mak, John J. L. Simard In a vast and rapidly growing body of information, the researcher, clinician and student need resources which bring into focus the latest developments in our understanding of the vertebrate immune system. A concise and up-to-date reference, Handbook of Immune Response Genes does just that. Starting with a brief overview of specific components of the immune system, the authors lead... |
 | Mechanisms of Tumor Escape from the Immune Response (Tumor Immunology and Immunotherapyseries, 1) The progressive growth of a malignant tumor is accompanied by a decline in the immune response, through mechanisms that have, until recently, been poorly understood. The new era of biological therapies, including cytokines, adoptive transfer of TIL cells, gene therapy and others, brought forth the need to understand the impact of the tumor on the immune system. Moreover, the inability to achieve... |
| Cellular Signaling and Innate Immune Responses to RNA Virus Infections | |
| Cell Interactions and Receptor Antibodies in Immune Responses by Anne And Kosunen, T.U. Cross | |
| Immune Responses in Parasitic Infections: Immunology, Immunopathology, and Immunoprophylaxis | |
| Regulation of the Immune Response |
| © 2008 BrightSurf.com |